Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresh Start For Insmed, Added Biosimilar Capabilities For Merck In $130M Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

By purchasing Insmed’s follow-on biologics pipeline and facility, Merck BioVentures is poised for bigger attack on Amgen blockbusters.

You may also be interested in...



Insmed Gets New Direction By Absorbing Transave And Lead Program Arikace

Transave execs will run new company focused on reformulation of amikacin for lung infections in cystic fibrosis patients.

Insmed Gets New Direction By Absorbing Transave And Lead Program Arikace

Transave execs will run new company focused on reformulation of amikacin for lung infections in cystic fibrosis patients.

On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era

The health care reform legislation signed into law by President Obama March 23 paves the way for the launch of biosimilar drugs in the U.S., action that could save the country's health care system billions of dollars, while presenting both challenges and opportunities for the drug industry

Related Content

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel